About this trial
Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL).
However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives.
O2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary .
The MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis.
The user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial.
Given the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it.
The purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Previously-diagnosed COPD or chronic ILD
Prescribed O2 for use with exertion at least 1 month prior to enrollment
Age 25 years old or greater
Self-reported stable symptoms and stable oxygen needs for at least 2 weeks
Disqualifiers
Active angina
Hemoglobin less than 10mg/dL
Musculoskeletal disease that precludes physical activity
Ongoing participation or plans for participation in pulmonary rehabilitation during the study
Trial design
Crossover
Treatments tested in this trial
MoblO2 control
DeviceFor the study, participants will be provided compressed gas oxygen tanks. The MoblO2 device will be attached to one D tank, and the other will be in reserve for if/when the first tank runs out, in which case, the MoblO2 device will be removed from the empty tank, attached to the reserve tank for use, and the first tank will be filled from the concentrator and left in reserve. For the next two weeks, whenever patients exert, they will be asked to use the D tanks with the MoblO2 system supplied by the study. During one of the weeks (Week A), the MoblO2 device will be in place atop the D cylinder and will collect data but not control O2 flow. For the other week (Week B), the MoblO2 device will be in place atop the D cylinder and will collect data and control O2 flow.
Treatment groups
Trial outcomes
Primary outcomes
Moderately vigorous physical activity (MVPA)
Time spent in moderately vigorous physical activity as assessed by actigraphy
Secondary outcomes
COPD Assessment Test
Symptom assessment for patients with COPD. The total score ranges from 0 to 40, with higher scores suggesting a greater impact of COPD on a patient's health.
Living with Pulmonary Fibrosis (L-PF) questionnaire scores
Disease specific questionnaire for patients with ILD. The L-PF is a 44-item questionnaire that yields six scores (Symptoms Module, Dyspnea domain, Cough domain, Energy domain, Impacts Module, and Total), each ranging from 0 to 100, with higher scores indicating worse symptoms or greater negative impact of disease.
Other outcomes
Oxygen use
O2 use each week, MoblO2 over-rides per week
Saturation outcomes
(Percent (%) time with SpO2 \< 90%, % time with SpO2 \< 88%, number of desaturation events \< 88% per hour
Patient reported outcome measures
International Physical Activity Questionnaire (long form) asks respondents to state how much time they spent doing various activities over the last seven days.
Patient reported outcome measures
PROactive Physical Activity in COPD (C-PPAC) instrument combines 14 items to generate a score ranging from 0-64, with higher scores indicating better status.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
National Jewish Health
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Stanford University
Collaborator
Minnesota Health Solutions
Collaborator
This trial is not recruiting at the moment. You can still explore other options: